415 related articles for article (PubMed ID: 31675427)
1. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Li L; Dai J; Natarajan Y; Yu X; Asch SM; El-Serag HB
Hepatology; 2020 Mar; 71(3):808-819. PubMed ID: 31675427
[TBL] [Abstract][Full Text] [Related]
2. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.
Yang JD; Ahmed F; Mara KC; Addissie BD; Allen AM; Gores GJ; Roberts LR
Hepatology; 2020 Mar; 71(3):907-916. PubMed ID: 31309602
[TBL] [Abstract][Full Text] [Related]
3. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
4. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
Chen J; Song S; Li X; Bian D; Wu X
Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
[TBL] [Abstract][Full Text] [Related]
5. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
6. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
Kramer JR; Natarajan Y; Dai J; Yu X; Li L; El-Serag HB; Kanwal F
Hepatology; 2022 Jun; 75(6):1420-1428. PubMed ID: 34779535
[TBL] [Abstract][Full Text] [Related]
7. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.
Natarajan Y; Kramer JR; Yu X; Li L; Thrift AP; El-Serag HB; Kanwal F
Hepatology; 2020 Oct; 72(4):1242-1252. PubMed ID: 32022277
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
10. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.
Navarroza AMC; Wong SN
Indian J Gastroenterol; 2021 Aug; 40(4):380-388. PubMed ID: 34213749
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.
Pais R; Lebray P; Rousseau G; Charlotte F; Esselma G; Savier E; Thabut D; Rudler M; Eyraud D; Vezinet C; Siksik JM; Vaillant JC; Hannoun L; Poynard T; Ratziu V
Clin Gastroenterol Hepatol; 2015 May; 13(5):992-9.e2. PubMed ID: 25459558
[TBL] [Abstract][Full Text] [Related]
13. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
[TBL] [Abstract][Full Text] [Related]
14. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
[TBL] [Abstract][Full Text] [Related]
15. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma.
Benhammou JN; Aby ES; Shirvanian G; Manansala K; Hussain SK; Tong MJ
Sci Rep; 2020 Jun; 10(1):9902. PubMed ID: 32555268
[TBL] [Abstract][Full Text] [Related]
16. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.
Méndez-Sánchez N; Cerda-Reyes E; Higuera-de-la-Tijera F; Salas-García AK; Cabrera-Palma S; Cabrera-Álvarez G; Cortez-Hernández C; Pérez-Arredondo LA; Purón-González E; Coronado-Alejandro E; Panduro A; Rodríguez-Hernández H; Cruz-Ramón VC; Valencia-Rodríguez A; Qi X; Hamdan-Pérez N; Aguilar-Olivos NE; Barranco-Fragoso B; Ramírez-Pérez O; Vera-Barajas A
F1000Res; 2020; 9():56. PubMed ID: 32595949
[No Abstract] [Full Text] [Related]
20. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.
Chan AW; Wong GL; Chan HY; Tong JH; Yu YH; Choi PC; Chan HL; To KF; Wong VW
J Gastroenterol Hepatol; 2017 Mar; 32(3):667-676. PubMed ID: 27547913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]